Dr Jeremy Braybrooke

BSc, BM, PhD, FRCP, Medical Oncologist

Languages spoken

English

Expert in

Breast cancer, testicular and Germ Cell cancer, chemotherapy, clinical trials and oncology

Enquiry

Refer a patient

Overview

Centres

Bristol

300 Park Avenue, Aztec West, Bristol BS32 4SY

01454 456500

Specialises in

Breast cancer

Treatments

Chemotherapy

Dr Jeremy Braybrooke is a Consultant Medical Oncologist and Associate Professor at University Hospitals Bristol and Weston NHS Foundation Trust. He has worked in Bristol since 2003 developing a research focused clinical practice specialising in breast and germ cell cancers. Jeremy is enthusiastic about improving patient’s experience of systemic anti-cancer therapies and is principal investigator on several trials. Jeremy also works one day per week with the Early Breast Cancer Trialists’ Collaborative Group in Oxford and part time with NICE as a Consultant Clinical Adviser in the Centre for Guidelines.

Career positions

Current position(s)

University Hospitals Bristol NHS Foundation Trust

Expertise and interests

Dr Braybrooke is an Honorary Senior Lecturer at the University of Bristol and actively involved in clinical research. He works part time as a Senior Clinical Research Fellow at the University of Oxford within the Early Breast Cancer Trialists Collaborative Group. This research seeks to bring together individual patient level data from all available randomised trials in early breast cancer. The published meta-analyses have had a significant impact on the management of patients with early stage breast cancer. He has co-authored over 40 peer-reviewed publications. Dr Braybrooke is a clinical advisor to NICE and sits on their technology appraisal committee reviewing the clinical and cost effectiveness of new treatments being considered for the NHS.

Professional association

Fellow of the Royal College of Physicians
Member of the American Society of Clinical Oncology

Member of the Association of Cancer Physicians

Accomplishments

Publications

Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-52
Early Breast Cancer Trialists’ Collaborative Group. Long term outcomes for neo-adjuvant versus adjuvant chemotherapy in early breast cancer. Meta-analysis of individual patient data from ten randomised trials. Lancet Oncology 2018; 19: 27-39

Pan H, Gray R, Braybrooke J et al. 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017; 377: 1836-46
Kuchel A, Robinson T, Comins C et al. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor positive early breast cancer – a prospective study. J. Cancer 2016; 29: 731-6